Conference Program

Registration

Session 1
New Approaches to the Treatment of Type 2 Diabetes
Session Chair: Dr. Ann Weber (Merck Research Laboratories)

Design and Synthesis of Orally Bioavailable Glucokinase Activators Producing Potent Anti-hyperglycemic Effects In Vivo
Matthew Fyfe, (OSI) Prosidion

The Development of Glucagon Receptor Antagonists for the Treatment of Type 2 Diabetes
Emma Parmee, Merck Research Laboratories

Discovery of Potent and Selective Inhibitors of Fructose-1,6-bisphosphatase with Potential as a New Class of Agents to Treat Type 2 Diabetes
Qun (Max) Dang, Metabasis Therapeutics

Design and Synthesis of Potent, Selective, and Orally Efficacious DPP4 Inhibitors Accelerated by High-Throughput Structural Biology
Stephen Gwaltney, Takeda San Diego

Welcome Reception/Mixer

Session 2
Improving the Failing Memory - Are We There Yet?
Session Chair: David Lowe, Memory Pharmaceuticals

Memory: From Molecules to Disease
Stephen Siegelbaum, Columbia University

Teaching Old Drugs New Tricks
Thorsten Melcher, Saegis Pharmaceuticals

11-beta- HSD1 Inhibitors and Cognition a Novel Approach to Memory Disorders
Xin Gu, Merck Research Laboratories

Modeling Cognitive Enhancement for the Treatment of Alzheimer’s Disease & Schizophrenia
Luca Santorelli, Roche

Measuring the Mind: Cognitive Testing in Drug Development
John Harrison, CPC Pharma & Radcliffe Hospital, Oxford

Lunch

Session 3
Microfluidics and Nano Scale Drug Discovery
Session Chair: Brian Warrington, University of Cambridge, Cambridge UK

Micro and Meso Flow Chemistry: The Way Forward
Steve Ley, University of Cambridge, UK

Flow Technology for Drug Discovery
Stephanie Wong-Hawkes, GlaxoSmithKline R&D Ltd, Harlow, UK

Applications of Nanotechnology in Drug Discovery
John Ryan, University of Oxford, UK

Point of Use Microfluidic Synthesis of Multiple PET Biomarkers
Joe Matteo, NanoTek LLC, Walland, TN

Poster Session 1

Session 4
Shutting the Door on Virus Entry
Session Chair: Nick Meanwell, Bristol-Myers Squibb

Inhibitors of HIV Attachment
John Kadow, Bristol-Myers Squibb

Dendrimer-based Virus Entry Inhibitors: From Discovery to the Clinic
Tom McCarthy, Starpharma Pty Limited

CCR5 Antagonists for HIV Therapy
Chris Barber, Pfizer, Sandwich UK

The Discovery of Orally Active Inhibitors of Respiratory Syncytial Virus
Nick Meanwell, Bristol-Myers Squibb

Structure-Based Design of Measles Virus Fusion-Protein Blockers
James P. Snyder, Emory University

Lunch - box lunches

Optional Tours

Session 5
Sodium Channel Blockers
Session Chair: Mark Murcko, Vertex

Voltage Sensing, Pore Opening, and Drug Block: The View from the Sodium Channel
William Catterall, University of Washington

Strategies to Discover Sodium Channel Blockers for Treating Pain
Gregory Kaczorowski, Merck Research Laboratories

Challenges and Strategies in Sodium Channel Drug Discovery
Johannes Krupp, Astra-Zeneca

Subtype Selective Sodium Channel Blockers. A Strategy towards the Treatment of Pain
Andreas Termin, Vertex Pharmaceuticals

Lunch / Poster Session 2

Session 6
ACS Med Chem Award Symposium
Session Chair: Rich Gibbs, Purdue University

The Role of Natural Products in Wyeth’s Discovery Research
Guy Carter, Wyeth Research

Structure Based Design of TACE Inhibitors
Jeremy Levin, Wyeth Research

Bioorganic Studies on Ginkgolides
Koji Nakanishi, Columbia University

Natural Products Through Bioorganic Chemistry – What’s Next?
Award Recipient: George Ellestad, Wyeth Research/Columbia University

Buses leave for dock

Optional Evening Dinner Banquet

Session 7
Late Breaking Session
Session Chair: Joel Barrish, Bristol-Myers Squibb

Varenicline, a Novel a4b2 nAChR Partial Agonist: Discovery, Pharmacology and Clinical Results in Smoking Cessation Trials
Jotham W. Coe, Research Fellow, Pfizer, Groton

Bradykinin B1 Receptor Antagonists as Novel Analgesics
Michael Wood, Senior Research Fellow, Merck, West Point

The Discovery of WAY-204688, (SIM-688), a Pathway Selective Inhibitor of NF-kB for Use in the Treatment for Rheumatoid Arthritis
Thomas Caggiano, Principal Research Scientist, Wyeth, Princeton

Discovery and Structure-Activity Relationships of Novel PPARalpha/gamma Dual Activators
Peter Cheng, Associate Director, Metabolic Diseases Chemistry, Bristol-Myers Squibb, Hopewell, NJ

Discovery of a Potent Orally ActiveTthrombin Receptor (protease activated receptor-1) Antagonist as a Novel Antiplatelet Agent
Sam Chackalamannil, Distinguished Fellow, CV/CNS Discovery Research, Schering-Plough Research Institute

Designing Small Molecule Neutral Endopeptidase Inhibitors for the Treatment of Female Sexual Dysfunction
Don S. Middleton, Senior Director, Discovery Chemistry, Pfizer, Sandwich

Lunch - sack lunches to go